---
$id: https://graph.org.ai/products/commodity/51131714
$type: Product
source: UNSPSC
code: "51131714"
title: "Anistreplase"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Anistreplase

**UNSPSC Code**: 51131714
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an acylated inactive complex of streptokinase and human lysine-plasminogen; after injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O8V541HJ6. European Medicines Agency schedules Anistreplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00538MIG. The term ANISTREPLASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29.) Most nations schedule Anistreplase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ANISTREPLASE remains the US FDA Preferred Term for this commodity. .

